OncologyTube.com is the first and only free video sharing website dedicated to helping oncology professionals spread knowledge about cancer research through video, audio and other multimedia.
    • OncologyTube Cancer Articles, News and Videos

      Site: OncologyTube Cancer Articles, News and Videos

    • Products & Pricing
      • Banner Advertising Plans
      • eNewsletter Packages
      • Pre-Roll Advertising
      • Create A Deep Dive Conversation
      • Create a Video Release (VR)
      • Boost Earned Media Only $60
    • 0
      • Portuguese
      • Spanish
      • Italian
      • Greek (Greece)
      • Sinhala
      • Polish
      • Arabic (Saudi Arabia)
      • Swedish (Sweden)
      • Portuguese (Brazil)
      • Hindi (India)
      • English (Australia)
      • Hebrew (Israel)
      • Czech
      • Hungarian (Hungary)
      • Chinese
      • Turkish
      • Japanese (Japan)
      • Dutch
      • French
      • German
      • Chinese (Traditional Han, Taiwan)
      • Korean (South Korea)
      • Thai
      • Spanish (Chile)
      • English (United States)
      • Russian
      • Danish (Denmark)
  • Home
  • Trending

  • Login

  • Quick Links
  • How To Self Record An Interview and Presentations
  • Schedule A Remote Interview!
  • Check Out Our Blog
  • Buy Advertising Banners
  • Buy Pre-Roll Advertisements
  • Boost Your Earned Media starting at Just $60
  • Create A Deep Dive Conversation
  • Advertising Specifications
  • Our Editorial Process
  • Publisher Calendar

  • Mobile
  • Connect Mobile App

  • Audio and Video
  • Videos
  • Audio

  • Channels
  • Browse Channels

  • Categories
  • Acute Lymphoblastic Leukemia 5594
  • Acute Myelogenous Leukemia 226
  • Bladder 96
  • Bone Metastases 5
  • Brain 79
  • Breast 548
  • Business Management 5
  • Cervical 16
  • Chronic Lymphocytic Leukemia 209
  • Chronic Myelogenous Leukemia 54
  • Colorectal 172
  • Conference Coverage 1
  • COVID-19 43
  • Gastrointestinal 177
  • General 341
  • Genitourinary 3
  • Head and Neck 110
  • Help 3
  • Hematologic Malignancies 206
  • Hodgkin Lymphoma 34
  • Imaging 2
  • Immunotherapy 179
  • Kidney 392
  • Liver 40
  • Lung 95
  • Lymphoma 235
  • Melanoma and Skin 107
  • Multiple Myeloma 535
  • Myeloproliferative Disease 37
  • News 149
  • Non-Hodgkin Lymphoma 81
  • Non-Small Cell Lung Cancer 554
  • Other 517
  • Ovarian 65
  • Pancreatic 102
  • Patient Resources 51
  • Pediatric 7
  • Prostate 300
  • Sarcoma 13
  • Sickle Cell 22
  • Small Cell Lung Cancer 81
  • Supportive Care 51
  • Testicular 3
  • Urology 16
  • Uterine 9

  • Install
  • Play a Link
  • About
  • Contact
  • Acute Lymphoblastic Leukemia
  • Acute Myelogenous Leukemia
  • Bladder
  • Bone Metastases
  • Brain
  • Breast
  • Business Management
  • Cervical
  • Chronic Lymphocytic Leukemia
  • Chronic Myelogenous Leukemia
  • Colorectal
  • Conference Coverage
  • COVID-19
  • Gastrointestinal
  • General
  • Genitourinary
  • Head and Neck
  • Help
  • Hematologic Malignancies
  • Hodgkin Lymphoma
  • Imaging
  • Immunotherapy
  • Kidney
  • Liver
  • Lung
  • Lymphoma
  • Melanoma and Skin
  • Multiple Myeloma
  • Myeloproliferative Disease
  • News
  • Non-Hodgkin Lymphoma
  • Non-Small Cell Lung Cancer
  • Other
  • Ovarian
  • Pancreatic
  • Patient Resources
  • Pediatric
  • Prostate
  • Sarcoma
  • Sickle Cell
  • Small Cell Lung Cancer
  • Supportive Care
  • Testicular
  • Urology
  • Uterine
Joel Neal, MD @JoelNealMD @StanfordMed @StanfordCancer @IASLC #SCLC #LungCancer #Cancer #Research Randomized Phase II Study of 3 Months or 2 Years of Adjuvant Afatinib
0:13:20

Joel Neal, MD @JoelNealMD @StanfordMed @StanfordCancer @I...

Joel Neal, MD, Ph.D., Associate Professor Of Medicine (Oncology) from Stanford Cancer Institute/Stanford University speaks about Randomized Phase II Study of 3 Months or 2 Years of Adjuvant Afatinib in Patients With Surgically Resected Stage I-III EGFR-Mutant Non–Small-Cell Lung Cancer.

Link to Article:
https://ascopubs.org/doi/abs/10.1200/PO.20.00301

Synopsis:

OBJECTIVE
Multiple studies suggest that epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) can delay cancer recurrence in patients with surgically resected disease. The amount of time that therapy must last in order to be effective is unknown.



SUMMARY
Patients with completely resected stage IA-IIIB EGFR-mutant non–small-cell lung cancer (American Joint Committee on Cancer 7th edition) after stage-appropriate standard-of-care adjuvant therapy were enrolled in this randomized phase II study. Patients were randomly assigned to receive adjuvant afatinib for 3 months or 2 years, starting at 30 mg daily by mouth. For the first three years, computed tomography imaging was done every six months, then once a year. The recurrence rate at 2 years after randomization was the primary study endpoint for this planned 92-patient trial. The goal was for a 20% improvement (from 70% after three months to 90% after two years).



OUTCOMES
A total of 46 patients were enrolled, with 45 of them receiving treatment. In the 3-month group, 96 percent (22/23) of patients completed their assigned course of afatinib treatment, compared to only 41 percent (9/22) in the 2-year group. The 3-month group had a recurrence-free survival rate of 70%, while the 2-year group had an RFS rate of 81 percent (P =.55). The 3-month group had a median RFS of 42.8 months, while the 2-year group had a median RFS of 58.6 months. Afatinib's side effects were similar to those previously reported.



FINAL REMARKS
Two years of adjuvant afatinib was found to be 11 percent less likely than three months of adjuvant afatinib in terms of recurrences. Because of under accuracy and early drug discontinuation in the 2-year group, this difference did not meet the primary study's 20% target. The optimal duration of adjuvant EGFR TKI therapy remains an important question, especially now that osimertinib is available with better efficacy and tolerability than earlier-generation agents.

51 Views
2 years Ago
Cancer News
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login

Small Cell Lung Cancer

The Skyscraper Trial: Treatments for Extensive Stage Small Cell Lung Cancer - ASCO Lung Review 2022
0:04:44
The Skyscraper Trial: Treatments for Extensive Stage Smal...
2 Views
2 months Ago
Cancer
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
REPLATINUM Phase III [2022] - Why does it matter? -Tony Reid, MD
REPLATINUM Phase III [2022] - Why does it matter? -Tony R...
513 Views
4 months Ago
Allen Wilbanks
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
REPLATINUM Phase III Trial Update [2022]
0:11:46
REPLATINUM Phase III Trial Update [2022]
1,171 Views
4 months Ago
Cancer News
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Podcast John Bushweller, PhD @UVA @UVACancerCenter #SCLC Discovery Suggests New Treatment: SCLC
0:05:11
Podcast John Bushweller, PhD @UVA @UVACancerCenter #SCLC ...
33 Views
1 year Ago
Cancer News
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
John Bushweller, PhD @UVA @UVACancerCenter #SCLC Discovery Suggests New Treatment: SCLC
0:05:11
John Bushweller, PhD @UVA @UVACancerCenter #SCLC Discover...
64 Views
1 year Ago
Cancer News
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Podcast - Melissa L. Johnson, MD @MLJohnsonMD2 @SarahCannonPR @SarahCannonDocs #SmallCellLungCancer #SCLC #Cancer #Research Results From the Phase 3 MERU Study
0:05:12
Podcast - Melissa L. Johnson, MD @MLJohnsonMD2 @SarahCann...
68 Views
1 year Ago
Cancer News
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Melissa L. Johnson, MD @MLJohnsonMD2 @SarahCannonPR @SarahCannonDocs #SmallCellLungCancer #SCLC #Cancer #Research Results From the Phase 3 MERU Study
0:05:12
Melissa L. Johnson, MD @MLJohnsonMD2 @SarahCannonPR @Sara...
42 Views
1 year Ago
Cancer News
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Professor William North @GeiselMed @CancerDartmouth @AlgernonPharma #SmallCellLungCancer #SCLC #Cancer #Research Algernon Pharmaceuticals Announces SCLC Ifenprodil Research Program and Ap...
0:09:35
Professor William North @GeiselMed @CancerDartmouth @Alge...
181 Views
1 year Ago
Cancer News
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Joel Neal, MD @JoelNealMD @StanfordMed @StanfordCancer @IASLC #SCLC #LungCancer #Cancer #Research Randomized Phase II Study of 3 Months or 2 Years of Adjuvant Afatinib
0:13:20
Joel Neal, MD @JoelNealMD @StanfordMed @StanfordCancer @I...
51 Views
2 years Ago
Cancer News
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Jared Weiss, MD @DrJaredWeiss @UNC_Lineberger @G1Therapeutics #ESSCLC #SmallCellLungCancer #Cancer #Research  FDA Approves First Therapy Developed to Help Protect Against Chemo Side Effects
00:07:11
Jared Weiss, MD @DrJaredWeiss @UNC_Lineberger @G1Therapeu...
71 Views
2 years Ago
Cancer News
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Jacob Scott, MD, DPhil @cancerconnecter @ClevelandClinic #LungCancer #GARD #Cancer #Research Combining Genomics and Mathematics Helps Personalize Radiation Therapy for Lung Cancer
00:12:11
Jacob Scott, MD, DPhil @cancerconnecter @ClevelandClinic ...
119 Views
2 years Ago
Cancer
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
ASCO Lung Cancer Roundtable - New Combinations Chemo Immunotherapy for Extensive Stage SCLC
00:04:42
ASCO Lung Cancer Roundtable - New Combinations Chemo Immu...
19 Views
2 years Ago
Cancer
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login

comments@oncologytube.com Copyright 2023 Medicus Networks, Inc. 45121 Morgan Heights Rd. Temecula, CA 92592